Consistent adoption across various R&D applications will drive the demand for mice models in the coming years on account of their similarity to human genomes.
Consistent adoption across various R&D applications will drive the demand for mice models in the coming years on account of their similarity to human genomes. The progressions in gene-editing tools and techniques like zinc-finger nuclease technology have made humanized mice models easily accessible to numerous research institutions and large firms across the developed countries.
The rising intake of personalized medicines across the globe has also increased the preference for mice model organisms. The National Institute of Aging (NIA) had revealed that humanized mice models are highly utilized in research for personalized medicines that are used to treat psychological disorders like Alzheimer’s disease.
It has been estimated that the global mice model market size will surpass USD 12.3 billion in yearly remuneration by 2026.
Potential in transgenic research and production & quality control
The annual revenue of the outbred mice model market reached more than USD 1.7 billion in 2019 owing to their higher adoption in transgenic research. The cost-effectiveness and improved fertility offered by outbred mice have increased their preference in comparison to their counterparts. These mice can be easily propagated by implementing non-standardized mating techniques that help to retain their substantial genetic variability.
The application of mice models across production and quality control is poised to rise at a prominent CAGR through 2026. This can be owed to their consistent requirement to inspect the safety of vaccines, particularly for malaria and tuberculosis. There is also an incessant need for personalized medicine and targeted therapies to treat cancer affected individuals. The National Center for Biotechnology Information (NCBI) stated that over 15% of the overall animal models consisting of mice witness high adoption in the production and quality control of vaccines.
Growth from CRISPR technology
The deployment of CRISPR technology will see a significant footprint due to its extensive use across neuroscience research. This technology offers an enhanced, simplified, cost-effective, and time-saving production of mice models over conventional methods. It also helps with the generation of mutant mouse models like knock-in and knockout mice models that are used in tests related to drug safety.
Furthermore, the incorporation of this technique has also assisted scientists to accurately manipulate the sequence of DNA. On account of these factors, the CRISPR technology segment in the mice model market registered a revenue share of over USD 2.5 billion in 2019.
To access sample pages of this report titled, “Mice Model Market Size By Mice Type (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Research and Development, {Infectious Disease, Immunological Diseases, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases}, Production and Quality Control, Academics), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-government}, Academic and Research Institutes, Contract Research Organizations (CROs)), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents, please click on the link below:
https://www.gminsights.com/request-sample/detail/4473
Increasing adoption in R&D
The mice model market share from the veterinary segment was responsible for 19% of the total remuneration in 2019. This value is anticipated to rise through 2026 with the increasing instances of animal health concerns like seizures and severe infectious diseases. This has urged the development of numerous veterinary medicines through R&D activities. The growth can be further attributed to the prominent presence of veterinary contract research organizations that provide mice models for veterinary drug discovery services. Also, multiple funds have been offered by the National Institute of Health (NIH) to render assistance in research projects that make use of these models.
Demand for mice models in companies is projected to rise at a 7.1% rate over the next few years due to the surge in the number of drugs. There is an incessant need for this end-user segment to test these drugs to check their efficacy and safety. Also, the rising instances of R&D activities across the pharmaceutical and biotechnology companies will boost the prospects for mice models in research.
Brazil to record considerable footprint
Brazil registered the highest share for the Latin America mice model market by contributing more than USD 11 million in 2019 on account of the prominent infrastructures and economic growth in the country. The expansion of the research sector across health, biotechnology, and pharmacology has increased the government support towards viral diseases, malaria, leishmaniasis, Chagas, and dengue. For instance, mouse models like CD1 and C57BL6 find extensive application in the study of the Zika virus that has sufficiently affected the regional population.
To add further, the regulation of the Brazilian health research policy has promoted partnerships and networks among scientists working across academic institutions to improve the quality of research while assuring animal welfare. The increasing episodes of domestic production, export, import, and consumption will lead to the development of various types of mice models by regional suppliers.
Competitive dynamics to enhance global presence
Solution providers in the mice model market are keen on various inorganic strategies to sustain the rising competition. For instance, The Jackson Laboratory and the Snyder-Robinson Foundation came up with two new mouse models to assist in the study of the Snyder-Robison Syndrome (SRS).
The current coronavirus pandemic has also added positive impetus to the use of laboratory mice. For instance, leading researchers in China produced a new mouse model by infecting the mice with the virus to carry out tests on the COVID-19 vaccine candidates.
The mice model market players are Charles River, genOway, Harbour BioMed, Hera BioLabs, Envigo, Taconic Biosciences, Inc, and Janvier Labs.
The global prevalence of neurodegenerative disorders has pushed the need for effective treatment as well as the prescription of precision medicines across various clinics and hospitals. The mouse-bearing human gene model (mutant SOD1) is extensively deployed to manufacture personalized therapeutics that are used in the treatment of the Amyotrophic Lateral Sclerosis (ALS) disease. Furthermore, precision drugs for Duchenne Muscular Dystrophy (DMD), are developed with the help of the mdx mouse.
About Global Market Insights, Inc.
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Website: https://www.gminsights.com